Evidence map›Paper›PMID 35611683›Full record

Trial reportESC heart failure2022

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure.

Kirsten Thiele, Matthias Rau, Niels-Ulrik Korbinian Hartmann, Marcus Möller, Julia Möllmann, Joachim Jankowski, András P Keszei, Michael Böhm, Jürgen Floege, Nikolaus Marx and 1 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 4 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 4 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. SGLT2 inhibitors and acute kidney injury.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Kirsten ThieleDepartment of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Matthias RauDepartment of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Niels-Ulrik Korbinian HartmannDepartment of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Marcus MöllerDepartment of Internal Medicine II, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Julia MöllmannDepartment of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Joachim JankowskiInstitute for Molecular Cardiovascular Research, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
András P KeszeiCenter for Translational & Clinical Research Aachen (CTC-A), RWTH Aachen University, Aachen, Germany.
Michael BöhmDepartment of Internal Medicine III, University Hospital Saarland, Saarland University, Homburg, Saar, Germany.
Jürgen FloegeDepartment of Internal Medicine II, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Nikolaus MarxDepartment of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Michael LehrkeDepartment of Internal Medicine I, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
Universitätsklinikum Aachen · DERWTH Aachen University · DESaarland University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsIn this prospective, placebo-controlled, double-blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patients with acute decompensated heart failure (HF). METHODS AND

resultsPatients with acute decompensated HF with or without diabetes were randomized to empagliflozin 10 mg or placebo for 30 days. Haemodynamic, laboratory, and urinary parameters were assessed after 6 h, 1 day, 3 days, 7 days, and 30 days of treatment. Median time between hospital admission and randomization was 72 h. Baseline characteristics were not different in the empagliflozin (n = 10) and placebo (n = 9) groups. Empagliflozin led to a significant increase in urinary glucose excretion throughout the study (baseline: 37 ± 15 mg/24 h; Day 1: 14 565 ± 8663 mg/24 h; P = 0.001). Empagliflozin did not affect the primary endpoint of cardiac index or on systemic vascular resistance index at any time point. However, empagliflozin significantly reduced parameters of AKI (urinary TIMP-2 and IGFBP7 by NephroCheck® as indicators of tubular kidney damage), which became significant after 3 days of treatment [placebo: 1.1 ± 1.1 (ng/mL)

conclusionsIn this study, empagliflozin treatment did not affect haemodynamic parameters but significantly reduced markers of tubular injury in patients with acute decompensated HF.

Indexed as

Acute Kidney InjuryHeart FailureBenzhydryl CompoundsBiomarkersGlucosidesHumansProspective StudiesBenzhydryl CompoundsBiomarkersempagliflozinGlucosidesAcute decompensated heart failureAcute kidney injuryEmpagliflozinHaemodynamic parametersSGLT2 inhibitors

Identifiers

PMID35611683
PMCPMC9288802
OpenAlexW4281572865

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.